Clinical Trial Update: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates multiple doses of natalizumab administered subcutaneously in Japanese participants with Relapsing-Remitting Multiple Sclerosis. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: TERMINATED | Results posted: 2025-11-25